AlphaStreet Newsdesk powered by AlphaStreet Intelligence
AXGN|EPS $0.07 vs $0.07 est (+0.0%)|Rev $61.5M|Net Loss $19.6MAxogen, Inc. (AXGN) reported first quarter 2026 results that met Wall Street expectations, delivering adjusted earnings per share of $0.07 alongside strong revenue growth as the peripheral nerve repair specialist continues to expand its commercial footprint. The company posted adjusted net income of $4.1M for the quarter as it scales its portfolio of nerve regeneration technologies.
Revenue totaled $61.5M for the quarter, up 26.6% from $48.6M in Q1 2025. The medtech company maintained healthy profitability metrics with gross margin of 75.2% for the quarter, reflecting the specialized nature of its nerve repair and regeneration products used in surgical procedures worldwide.
For the full year, management expects revenue of $270.0M as Axogen works to drive adoption of its peripheral nerve solutions across hospitals and surgical centers. The company’s products address nerve injuries and discontinuities, serving a market that includes trauma, orthopedic, and plastic and reconstructive surgeries.
Wall Street maintains a positive outlook on the stock, with consensus standing at 11 buy, 1 hold, and 0 sell ratings. The combination of double-digit revenue growth and positive earnings signals continued momentum in Axogen’s commercial execution as it builds on its leadership position in peripheral nerve repair technologies.
A detailed analysis of Axogen, Inc.’s quarter follows shortly on AlphaStreet.
This content is for informational purposes only and should not be considered investment advice. AlphaStreet Intelligence analyzes financial data using AI to deliver fast and accurate market information. Human editors verify content.